2705, boulevard Laurier
R-00-771
Québec, Québec
Canada G1V 4G2
Dernières nouvelles
Information non disponible
In Memoriam: Fernand Labrie, June 28, 1937 – January 16, 2019
Article de revueSex Med Rev, 7 (2), 2019.
Effect of intravaginal dehydroepiandrosterone (DHEA) on the female sexual function in postmenopausal women: ERC-230 open-label study
Article de revueHorm Mol Biol Clin Investig, 25 (3), 2016.
Efficacy of intravaginal dehydroepiandrosterone (DHEA) on moderate to severe dyspareunia and vaginal dryness, symptoms of vulvovaginal atrophy, and of the genitourinary syndrome of menopause
Article de revueMenopause, 23 (3), 2016.
Effect of Intravaginal Prasterone on Sexual Dysfunction in Postmenopausal Women with Vulvovaginal Atrophy
Article de revueJ Sex Med, 12 (12), 2015.
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone)
Article de revueMenopause, 22 (9), 2015.
Lack of effect of intravaginal dehydroepiandrosterone (DHEA, prasterone) on the endometrium in postmenopausal women
Article de revueMenopause, 22 (12), 2015.
Prasterone has parallel beneficial effects on the main symptoms of vulvovaginal atrophy: 52-week open-label study
Article de revueMaturitas, 81 (1), 2015.
Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women
Article de revueJ Sex Med, 11 (7), 2014.
Intravaginal prasterone (DHEA) provides local action without clinically significant changes in serum concentrations of estrogens or androgens
Article de revueJ Steroid Biochem Mol Biol, 138 , 2013.
Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia
Article de revueClimacteric, 14 (2), 2011.